185 related articles for article (PubMed ID: 1382234)
1. Intensive combination chemotherapy (TTL-I protocol) of large cell and immunoblastic lymphomas--long-term observation.
Koza I; Mardiak J; Bohunický L; Svancárová L; Fuchsberger P; Gyárfás J; Horák I; Spánik S; Sufliarsky J; Thalmeinerová Z
Neoplasma; 1992; 39(1):43-7. PubMed ID: 1382234
[TBL] [Abstract][Full Text] [Related]
2. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
[TBL] [Abstract][Full Text] [Related]
3. Randomized study comparing doxorubicin, cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (ACOMLA) with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-B) in the treatment of diffuse histiocytic lymphoma.
Newcomer LN; Cadman EC; Nerenberg MI; Chen M; Bertino JR; Farber LR; Prosnitz LR
Cancer Treat Rep; 1982 Jun; 66(6):1279-84. PubMed ID: 6177407
[TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy for advanced non-Hodgkin's lymphomas other than diffuse histiocytic or undifferentiated histologies.
Anderson KC; Skarin AT; Rosenthal DS; MacIntyre JM; Pinkus GS; Case DC; Leonard RC; Canellos GP
Cancer Treat Rep; 1984 Nov; 68(11):1343-50. PubMed ID: 6209007
[TBL] [Abstract][Full Text] [Related]
5. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
6. MACOP-B chemotherapy for malignant lymphomas and related conditions: 1987 update and additional observations.
Connors JM; Klimo P
Semin Hematol; 1988 Apr; 25(2 Suppl 2):41-6. PubMed ID: 2456622
[TBL] [Abstract][Full Text] [Related]
7. [The treatment of large-cell non-Hodgkin's lymphomas with the MACOP-B protocol].
Montalbán C; Rodríguez García JL; Marcos Robles J; Serrano M; Arechaga S; Perales J; Bellas C
Med Clin (Barc); 1991 Oct; 97(14):521-5. PubMed ID: 1721672
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of medium and highly malignant non-Hodgkin's lymphoma with combined chemotherapy using methotrexate, adriamycin, cyclophosphamide, vincristine, prednisone and bleomycin (protocol MACOP-B)].
Pittrová H; Koza V; Vozobulová V; Cetkovský P; Skopek P; Jungerová J; Cepelák V
Vnitr Lek; 1989 Dec; 35(12):1177-82. PubMed ID: 2483776
[TBL] [Abstract][Full Text] [Related]
9. [CAMBO-VIP for advanced diffuse large cell lymphoma (LSG classification)--a long-term follow-up study].
Okamoto M; Maruyama F; Tsuzuki M; Nomura T; Miyazaki H; Wakita M; Kojima H; Sobue R; Matsui T; Ino T
Gan To Kagaku Ryoho; 1994 Jan; 21(1):67-73. PubMed ID: 7507314
[TBL] [Abstract][Full Text] [Related]
10. ProMACE-CytaBOM: combination chemotherapy for diffuse large cell lymphoma.
Prokocimer M; Modan M; Rusoshansky S; Bairey O; Shaklai M
Anticancer Res; 1989; 9(4):1233-5. PubMed ID: 2479327
[TBL] [Abstract][Full Text] [Related]
11. Low dose methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone with zalcitabine in patients with acquired immunodeficiency syndrome-related lymphoma. Effect on human immunodeficiency virus and serum interleukin-6 levels over time.
Levine AM; Tulpule A; Espina B; Boswell W; Buckley J; Rasheed S; Stain S; Parker J; Nathwani B; Gill PS
Cancer; 1996 Aug; 78(3):517-26. PubMed ID: 8697399
[TBL] [Abstract][Full Text] [Related]
12. Avascular necrosis of bone mimicking symmetric polyarthritis in a patient with malignant lymphoma treated with high-dose steroids.
Buskila D; Thomson GT; Klein M; Keystone EC
Isr J Med Sci; 1992 Nov; 28(11):804-5. PubMed ID: 1281809
[No Abstract] [Full Text] [Related]
13. [Treatment of primary mediastinal large B-cell lymphomas].
Schneider T; Tóth E; Molnár Z; Várady E; Deák B; Horváth A; Horváth GI; Eid H; Schneider K; Lovey J; Keresztes S; Esik O; Lengyel Z; Rosta A
Orv Hetil; 2004 Dec; 145(50):2531-7. PubMed ID: 15662753
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma.
Akpek G; Koh HK; Bogen S; O'Hara C; Foss FM
Cancer; 1999 Oct; 86(7):1368-76. PubMed ID: 10506727
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
[TBL] [Abstract][Full Text] [Related]
16. The m-BACOD combination chemotherapy regimen in the treatment of diffuse large cell lymphoma.
Canellos GP; Skarin AT; Klatt MM; Rosenthal DS; Case DC; Pinkus GS; Jochelson MS; Yeap BY; Shipp MA
Semin Hematol; 1987 Apr; 24(2 Suppl 1):2-7. PubMed ID: 2438777
[TBL] [Abstract][Full Text] [Related]
17. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
[TBL] [Abstract][Full Text] [Related]
18. Treatment of diffuse non-Hodgkin's lymphoma with combined chemotherapy using methotrexate, adriamycin, cyclophosphamide, vincristine, prednisolone and bleomycin (MACOP-B).
Sawada U; Yamazaki T; Suzuki K; Ashiya M; Satou Y; Hirano H; Tsuboi I; Sakuma A; Kura Y; Kouda K
Int J Hematol; 1992 Aug; 56(1):59-66. PubMed ID: 1382663
[TBL] [Abstract][Full Text] [Related]
19. Methotrexate as a single agent and in combination chemotherapy for the treatment of non-Hodgkin's lymphoma of unfavorable histology.
Canellos GP; Skarin AT; Rosenthal DS; Moloney WC; Frei E
Cancer Treat Rep; 1981; 65 Suppl 1():125-9. PubMed ID: 6173118
[TBL] [Abstract][Full Text] [Related]
20. [Clinical usefulness of ondansetron hydrochloride for nausea and vomiting during repeated courses of chemotherapy for malignant lymphoma--impact of prognosis announcement on anti-emetic effect and evaluation of patient perception of chemotherapy-associated adverse events].
Kodama F; Mohri H; Motomura S; Fukawa H; Tanabe J; Koharasawa H; Kanamori H; Hashimoto Y; Harano H; Sakai R; Tomita N; Fujimaki K; Takemura S; Hattori M
Gan To Kagaku Ryoho; 2002 Feb; 29(2):273-9. PubMed ID: 11865634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]